Mavrilimumab in Severe COVID-19 Pneumonia and Hyper-inflammation (COMBAT-19) : A Randomized, Double Blind, Placebo-controlled Trial of Mavrilimumab for Acute Respiratory Failure Due to COVID-19 Pneumonia With Hyper-inflammation (the COMBAT-19 Trial)
This study is a prospective, phase II, multi-center, randomized, double-blind, placebo-controlled trial to evaluate the efficacy and safety of mavrilimumab in hospitalized patients with acute respiratory failure requiring oxygen supplementation in COVID- 19 pneumonia and a hyper-inflammatory status. The study will randomize patients to mavrilimumab or placebo, in addition to standard of care per local practice. The total trial duration will be 12 weeks after single mavrilimumab or placebo dose..
Medienart: |
Klinische Studie |
---|
Erscheinungsjahr: |
2020 |
---|---|
Erschienen: |
2020 |
Enthalten in: |
ClinicalTrials.gov - (2020) vom: 26. Mai Zur Gesamtaufnahme - year:2020 |
---|
Sprache: |
Englisch |
---|
Links: |
Volltext [kostenfrei] |
---|
Anmerkungen: |
Source: Link to the current ClinicalTrials.gov record., First posted: May 21, 2020, Last downloaded: ClinicalTrials.gov processed this data on June 14, 2021, Last updated: June 15, 2021 |
---|
Study ID: |
NCT04397497 |
---|---|
Veröffentlichungen zur Studie: |
|
fisyears: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
CTG003398811 |
---|
LEADER | 01000caa a22002652 4500 | ||
---|---|---|---|
001 | CTG003398811 | ||
003 | DE-627 | ||
005 | 20230425231038.0 | ||
007 | cr uuu---uuuuu | ||
008 | 210408s2020 xx |||||o 00| ||eng c | ||
035 | |a (DE-627)CTG003398811 | ||
035 | |a (UBBS_Klinische_Studien)NCT04397497 | ||
035 | |a (UBBS_Klinische_Studien)COMBAT-19 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
245 | 1 | 0 | |a Mavrilimumab in Severe COVID-19 Pneumonia and Hyper-inflammation (COMBAT-19) |b A Randomized, Double Blind, Placebo-controlled Trial of Mavrilimumab for Acute Respiratory Failure Due to COVID-19 Pneumonia With Hyper-inflammation (the COMBAT-19 Trial) |
264 | 1 | |c 2020 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a Computermedien |b c |2 rdamedia | ||
338 | |a Online-Ressource |b cr |2 rdacarrier | ||
500 | |a Source: Link to the current ClinicalTrials.gov record., First posted: May 21, 2020, Last downloaded: ClinicalTrials.gov processed this data on June 14, 2021, Last updated: June 15, 2021 | ||
520 | |a This study is a prospective, phase II, multi-center, randomized, double-blind, placebo-controlled trial to evaluate the efficacy and safety of mavrilimumab in hospitalized patients with acute respiratory failure requiring oxygen supplementation in COVID- 19 pneumonia and a hyper-inflammatory status. The study will randomize patients to mavrilimumab or placebo, in addition to standard of care per local practice. The total trial duration will be 12 weeks after single mavrilimumab or placebo dose. | ||
650 | 2 | |a Pneumonia, Viral | |
650 | 2 | |a Pneumonia | |
650 | 2 | |a Respiratory Insufficiency | |
650 | 2 | |a Respiratory Distress Syndrome, Adult | |
650 | 2 | |a Inflammation | |
650 | 4 | |a Medical Condition: Covid-19, Acute Respiratory Failure, ARDS, Human, Sars-CoV2, Viral Pneumonia | |
650 | 4 | |a Study Type: Interventional | |
650 | 4 | |a Recruitment Status: Not yet recruiting | |
650 | 4 | |a Phase: Phase 2 | |
650 | 4 | |a 610 | |
773 | 0 | 8 | |i Enthalten in |t ClinicalTrials.gov |g (2020) vom: 26. Mai |
773 | 1 | 8 | |g year:2020 |g day:26 |g month:05 |
856 | 4 | 0 | |u https://clinicaltrials.gov/show/NCT04397497 |z kostenfrei |3 Volltext |
912 | |a GBV_CTG | ||
912 | |a SSG-OLC-PHA | ||
951 | |a AR | ||
952 | |j 2020 |b 26 |c 05 |